Calcium channel blockers and risk of AD: the Baltimore Longitudinal Study of Aging.
about
Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementiaAntihypertensive agents and risk of Parkinson's disease, essential tremor and dementia: a population-based prospective study (NEDICES).Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association.NILVAD protocol: a European multicentre double-blind placebo-controlled trial of nilvadipine in mild-to-moderate Alzheimer's disease.Blood pressure and dementia - a comprehensive review.Antihypertensive withdrawal for the prevention of cognitive decline.Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention.Hypertension and cognitive functionAntihypertensive drugs, prevention of cognitive decline and dementia: a systematic review of observational studies, randomized controlled trials and meta-analyses, with discussion of potential mechanisms.Calcium channel blocking as a therapeutic strategy for Alzheimer's disease: the case for isradipine.Potential for specific dihydropyridine calcium channel blockers to have a positive impact on cognitive function in humans: a systematic review.Amlodipine, an L-type calcium channel blocker, protects against chlorpromazine-induced neurobehavioural deficits in mice.Treatment options and considerations for hypertensive patients to prevent dementia.Cardiac risk factors and potential treatments in Alzheimer's disease.A 10-year follow-up study of the association between calcium channel blocker use and the risk of dementia in elderly hypertensive patientsDementia prevention: methodological explanations for inconsistent results.Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors.Calcium channel blockers and dementia.Dantrolene, a treatment for Alzheimer disease?Anticholinesterase and antioxidant investigations of crude extracts, subsequent fractions, saponins and flavonoids of atriplex laciniata L.: potential effectiveness in Alzheimer's and other neurological disorders.Selective antihypertensive dihydropyridines lower Aβ accumulation by targeting both the production and the clearance of Aβ across the blood-brain barrier.Progress in the development of new drugs in Alzheimer's disease.Amlodipine treatment of hypertension associates with a decreased dementia risk.Demonstration of safety in Alzheimer's patients for intervention with an anti-hypertensive drug Nilvadipine: results from a 6-week open label study.Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial
P2860
Q24240206-1E755BFD-90D6-48D3-B9BB-7B3614523533Q33678373-0DE13AC0-E591-4A33-9196-90AE3168C320Q33967781-C6EDA2AE-8AFB-4846-B181-AB14B463C5EDQ34327761-C99FB7C7-1BE9-4389-ADDF-8CCFC083FA1CQ34409397-B2AE17A5-D993-4ED9-89A4-2FD6395113FEQ34543877-F1FD06B6-519E-47CF-9E1A-64E3AC530D65Q34991223-A700BC70-7823-437F-8CDB-B64B0F11AA56Q35178724-A3AFDCE6-1372-47DC-A351-666533912307Q35564715-C4DC4F29-0CC3-4259-9F3A-E2030C157788Q35743824-A7579315-1028-4DD0-9B97-017887079252Q35780850-326A3E69-1B55-4C4F-BCA9-7AF946C6C9ECQ36254230-A33F1EA3-F19C-4197-8BA5-BE5863AB7164Q36377901-8D1F43C6-0182-44CA-B72D-25D82801D093Q36582769-83B2CC0D-6F2F-4EAE-83BC-60F70D3691D0Q37176098-788AA257-33BF-4277-873E-BEB9315A8847Q37263684-DEA78C7B-1BD9-4738-9E8B-2F5B3E5CD0C3Q37600876-DCA76EB9-EA65-408C-91C5-603034098972Q38103603-2C1B903A-7384-4353-AC06-656F91149E45Q38304771-15D8B30C-DB74-4040-9493-BD579382C5D7Q39525423-10ADBBD3-4734-4A0C-9CD5-0B016FE86630Q39618144-AD5F693C-B889-4111-A014-5031291BDE2AQ39789745-C5527D87-5973-4CE7-BC50-60966406AA73Q40661217-99CEB6B6-EF63-419B-A107-3735111BAF7AQ53322014-41583502-2E40-4EFA-9E5C-BC97A723B56EQ58701472-963B94A3-9741-42AF-B71D-8AFB7017F92B
P2860
Calcium channel blockers and risk of AD: the Baltimore Longitudinal Study of Aging.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Calcium channel blockers and risk of AD: the Baltimore Longitudinal Study of Aging.
@en
Calcium channel blockers and risk of AD: the Baltimore Longitudinal Study of Aging.
@nl
type
label
Calcium channel blockers and risk of AD: the Baltimore Longitudinal Study of Aging.
@en
Calcium channel blockers and risk of AD: the Baltimore Longitudinal Study of Aging.
@nl
prefLabel
Calcium channel blockers and risk of AD: the Baltimore Longitudinal Study of Aging.
@en
Calcium channel blockers and risk of AD: the Baltimore Longitudinal Study of Aging.
@nl
P2093
P1476
Calcium channel blockers and risk of AD: the Baltimore Longitudinal Study of Aging
@en
P2093
P304
P356
10.1016/J.NEUROBIOLAGING.2004.03.009
P577
2005-02-01T00:00:00Z